Dr. Charles A. Roach, MD
Neurology (Neurology Physician)
4921 Parkview Pl, Div Neurology Neuromuscular, Ste 6c
Saint Louis, MO 63110
- Medicare participating
At a glance
- Medical school
- University of Kansas School of Med (Kc/Wich/Sal) (2018)
- Years since graduation
- 8
- In the NPI registry since
- 2018
- Medicare patients seen, 2024
- 242
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2018Medical school: University of Kansas School of Med (Kc/Wich/Sal)
- 2018Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
MO license 2022005437
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Barnes Jewish Hospital Saint Louis, MO
- Barnes-Jewish West County Hospital Creve Coeur, MO
- Memorial Hospital Belleville, IL
Medical groups
- Washington University (3,029 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 242
- Services billed
- 729
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 32 | 29 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 21 | 20 |
| New patient office or other outpatient visit, 60-74 minutes | 19 | 19 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 16 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisone Other prescribers in Saint Louis, MO | 85 |
| Gabapentin Other prescribers in Saint Louis, MO | 60 |
| Duloxetine Hcl Other prescribers in Saint Louis, MO | 57 |
| Riluzole | 52 |
| Radicava Ors (edaravone) | 41 |
| Pregabalin Other prescribers in Saint Louis, MO | 36 |
| Methotrexate (methotrexate sodium) Other prescribers in Saint Louis, MO | 33 |
| Oxcarbazepine Other prescribers in Saint Louis, MO | 32 |
| Atropine Sulfate | 29 |
| Methylprednisolone Sodium Succ (methylprednisolone sod succ) | 23 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 11 payments worth $1,518 in total to this clinician.
| Takeda Pharmaceuticals U.S.A., Inc. | $1,472 |
|---|---|
| Argenx US, Inc. | $45.75 |
| Travel and Lodging | $1,141 |
|---|---|
| Food and Beverage | $376 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. Oct 3, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind | $441 |
| Takeda Pharmaceuticals U.S.A., Inc. Oct 2, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind | $259 |
| Takeda Pharmaceuticals U.S.A., Inc. Oct 2, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind | $232 |
| Takeda Pharmaceuticals U.S.A., Inc. Oct 3, 2025 | Travel and Lodging travel to MIAMI, FL · in-kind | $209 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 2 companies. The companies reported $29,717 in research payments for these studies, mostly to the institutions running them.
- A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Sanofi US Services Inc. · Recruiting · NCT06290141 - A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work
Sanofi US Services Inc. · Active, not recruiting · NCT06290128 - A Phase 3 Single Arm Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Subcutaneous (Human), 20% Solution with Recombinant Human Hyaluronidase (TAK-881) for the Treatment of Chronic Inflamm…
Takeda Pharmaceuticals U.S.A., Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.